New Delhi: India’s indigenous COVID-19 vaccine, Covaxin, was found to have an efficacy rate of 77.8 per cent against symptomatic COVID-19, according to a long-awaited analysis published in The Lancet.
Covaxin is developed by the India government’s medical research agency and Hyderabad-based Bharat Biotech International Ltd.
Covaxin, which uses traditional, inactivated-virus technology, “induces a robust antibody response” two weeks after two doses are given, the medical journal was quoted as saying in a statement by Bloomberg.
The trial involving 24,419 participants aged 18-97 years between November 2020 and May 2021 in India found no vaccine-related deaths or adverse events, the journal said.
Funded by Bharat Biotech and the Indian Council of Medical Research (ICMR) and partially authored by officials at both bodies, the interim study was in line with the company’s earlier efficacy and safety announcements.
ALSO READ: UK Approves Covaxin; No Quarantine For Fully Vaccinated Travellers
Bhubaneswar: New facts are coming to light con woman Hansita Abhilipsa, who has been arrested…
Bhubaneswar: A 55-year-old farmer alleged died by suicide while protesting at Shambhu border point between…
Bhubaneswar: The chilly weather conditions may continue in Odisha for another two days, following which…
Bhubaneswar: Ration cards of beneficiaries would be cancelled by the Odisha government if they fail…
Bhubaneswar: The brutal murder of police 'mitra' (volunteer), Sahadeb Nayak (36), on Rasulgarh overbridge in…
Bhubaneswar: A day after President of BMC Sanitation Employees’ Association president Sahadev Nayak was hacked…
This website uses cookies.
